NCT05090280 - Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101) | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

April 26, 2023

Study Completion Date

April 26, 2023

Conditions

Pharmacokinetics

Interventions

DRUG

PF614 solution

PF614 solution is an oxycodone prodrug

DRUG

Naltrexone Hydrochloride

Naltrexone 50 mg has been selected to be administered on Day -1 (single dose), Day 1 (BID), and Day 2 (single-dose) to reduce opioid-related adverse effects.

DRUG

Nafamostat Mesylate

Maximum dose of 10 mg nafamostat co-administered with PF614 solution. Nafamostat will be dosed as an immediate-release (IR) solution or as prototype extended-release (ER) capsules.

Trial Locations (1)

33126

Quotient Sciences, Miami